Meningitis under the microscope

5 May 2026 · 28 min · 12 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Bacterial meningitis (Neisseria meningitidis) biology, symptoms, diagnosis, treatment, prevention via vaccines, and how UKHSA responds to outbreaks, including the Kent outbreak.

Guests

Robin May, Chief Scientific Officer at UK Health Security Agency (UKHSA). Kat Sharrocks, consultant in infectious diseases at Addenbrooke’s Hospital, Cambridge. Professor Sir Andrew Pollard, director of the Oxford Vaccine Group.

Key claims

Carried in noses/throats by some healthy people (up to ~1 in 4), but invasive disease can occur abruptly and can cause sepsis. Symptoms often include fever, headache, light sensitivity, neck stiffness, confusion/sleepiness; rash may occur but absence doesn’t rule it out. Diagnosis uses blood tests, CT, and lumbar puncture. Start antibiotics and dexamethasone immediately when suspected. Vaccines reduce cases but don’t fully protect due to multiple serogroups/strains.

Notable examples

Kent outbreak in south-east England—nearly 30 young people, two deaths; linked to a nightclub and a MenB-dominated strain. UKHSA actions: contact tracing, sequencing to identify strain links, treating thousands with antibiotics, and ring vaccination (protects individuals but doesn’t eliminate carriage).

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Understanding Bacterial Meningitis

0:58 to 2:29

Explore the causes, symptoms, and seriousness of bacterial meningitis.

“I'm Chris Smith and today bacterial meningitis is going under our microscope.”

Risk Factors and Statistics

2:29 to 4:25

Discuss who is most at risk for bacterial meningitis and its historical prevalence.

“It can get infected, it can get inflamed and that's obviously very dangerous as with all infections of the central nervous system.”

Transmission and Outbreaks

4:25 to 6:22

Learn how bacterial meningitis spreads and the response to outbreaks.

“So babies, very young children, and then in teenage age and then dropping off, you're likely to get this drops off as you get older.”

Symptoms and Diagnosis

6:22 to 8:34

Identify the symptoms of bacterial meningitis and how it's diagnosed.

“start to look for, for example, members of their family, boyfriends, girlfriends, close friends with whom they may have had close contact in order to check for transmission and to treat those people.”

Treatment Approaches

8:34 to 10:34

Understand the treatment protocols for bacterial meningitis cases.

“in our bloodstream and that's what leads to that particular rash, that rash that doesn't go away when you put a glass on top of it.”

Prognosis and Long-term Outcomes

10:34 to 13:52

Discuss the potential outcomes and complications after treatment.

“If you pick it up, God forbid, and you discover there is all the evidence there is a bacterial infection there, what do you do?”

Understanding Bacterial Meningitis

14:28 to 15:09

Exploration of bacterial meningitis, its causes, and preventive measures.

“Just now we were hearing how to recognise, diagnose and treat cases of bacterial meningitis but prevention is always better than cure and this is where vaccines come in.”

Vaccine Effectiveness and Age Susceptibility

15:10 to 18:19

Discussion with Professor Pollard about vaccine types and their effectiveness across age groups.

“I asked Professor Sir Andrew Pollard who is director of the Oxford Vaccine group to give us a roundup of what's being used and how effective they all are.”

Vaccine Protection Duration

18:20 to 21:02

Analysis of how long vaccine protection lasts and its importance for specific age groups.

“What we don't know at the moment is whether if you're vaccinated as an infant, it would still protect you one or two decades later.”

Public Health Response to Outbreaks

21:03 to 21:32

Insight into how public health bodies respond to meningitis outbreaks.

“group as we heard earlier thanks to vaccination cases of bacterium meningitis have fallen markedly in countries like the UK in recent years.”
Show all 12 chapters

Genetic Sequencing and Its Importance

21:33 to 22:24

Discussion on the significance of genetic information during meningitis outbreaks.

“If you're a clinician with a patient with suspected meningitis, please don't wait for it to be confirmed.”

Investigating the Recent Kent Outbreak

22:25 to 27:21

Examination of the unique circumstances and factors contributing to the Kent meningitis outbreak.

“but does it tell us anything about virulence, why this particular strain may or may not be nasty?”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Kat Sharrocks:You don't need a passport to taste the world's most luxurious beef. Just head to Benihana. Introducing the Wagyu of the World menu. From the rich flavor of American masami ribeye to the bold Australian New York strip to the legendary melt-in-your-mouth A5 Japanese Wagyu, this is the finest beef on the planet, expertly grilled right at your table. Why settle for an ordinary steak dinner when you can taste the world in one bite? Only at Benihana. Book your table at BennyHanna.com.

0:57Robin May:and medicine. I'm Chris Smith and today bacterial meningitis is going under our microscope.

1:15Robin May:Bacterial meningitis is a serious but thankfully now relatively uncommon infection which is caused most often by the meningococcus bacterium, Neisseria meningitidis. And believe it or not, this is actually commonly carried in our noses and throats. In some instances, as many as one person in four are found to be harbouring it, although in the majority of those cases, it causes absolutely no problems whatsoever. But in some people, infected with certain forms of the bug and perhaps in response to another antecedent infection or a problem with their immune system, it can become invasive, spreading through the bloodstream to involve the meninges, the tissues surrounding the brain, and also triggering sepsis.

1:59Robin May:The onset is often very abrupt, catching people completely unawares. A recent outbreak in Kent in the south-east of England was extraordinary in hitting nearly 30 young people, of whom two later died. So we thought we'd delve into the biology of bacterial meningitis, find out how it causes disease, how to recognise and treat it and what vaccines can do to prevent it and also how to handle outbreaks when they happen which is the role of the UK Health Security Agency. Robin May is the organisation's chief scientific officer.

2:32Kat Sharrocks:So meningitis refers to a group of conditions which is essentially characterised by inflammation of the meninges and the meninges is a layer on the outside of the brain and spinal cord that kind of protects the brain from damage. It can get infected, it can get inflamed and that's obviously very dangerous as with all infections of the central nervous system. Different organisms can cause meningitis so you could have viral meningitis caused by actually quite a range of viruses. You could have fungal meningitis in some rare cases caused by fungi but the one that we're talking about primarily today is bacterial meningitis which is caused by a bacterial species called Neisseria meningitidis.

3:11Robin May:There are other microbes that can do it though it's not just Neisseria meningitis is it because when we go to medical school they tell us to keep our eyes open for a range of things yeah there are there's quite a

3:22Kat Sharrocks:wide range actually and some of those are kind of quite well able to do this and some it's a very rare complication so for instance there are some you know very rare fungal infections that people only get when they have underlying immunocompromised conditions like HIV but in rare cases they can go to the brain too and causes kind of meningitis. But I think the one that is particularly dominant in people's minds and has occupied the media a lot recently is this one that is bacterial meningitis transmitted between people who are healthy, particularly young people. And so that's one that is very prominent and one that people should be on the alert for and on the lookout for.

4:00Robin May:Who tends to get it and where do they tend to get it? I don't mean in terms of in their body, I mean geographically.

4:07Kat Sharrocks:Yeah, so these are diseases that are widespread. So if we think about, If we focus on bacterial meningitis caused by Neisseria, this bacteria we're talking about, it's found all over the world. So people can get it anywhere. Actually, anyone can get it. But if you look at the most likely candidates to get it, it is typically associated with age. So babies, very young children, and then in teenage age and then dropping off, you're likely to get this drops off as you get older. And that's largely because we're exposed to this bacteria. It's a bacteria that is prevalent in the world. so we're exposed to it and develop a kind of natural immunity over time and obviously also in many countries including the uk we have vaccination programs that have really reduced the level of this so if you're one of those countries you also gain the benefit of vaccination as you age but yeah so this is largely a disease bacterium energitis a larger disease of babies

4:57Robin May:and infants and then again in teenage years what sorts of numbers do we see is this a rare thing or is it actually quite common but flying under most people's radars?

5:08Kat Sharrocks:Historically, this was kind of alarmingly common. We have done a pretty good job in recent decades actually of reducing numbers through vaccination programme in the UK. And now all children get vaccines when they're shortly after they're born. And they have been very, very effective in reducing the amount of disease. Two things to say about that though, I think. One is that this is a very complicated bacteria. It comes in lots of different flavours, also called serogroups. And generally, the vaccines work against any one serogroup. So what you now get as a baby is a vaccine that protects you against four different strains of this.

5:43Kat Sharrocks:But there are about 12 common strains of meningitis around the world, bacteria meningitis around the world. So you're not fully protected. And so even when you're vaccinated, you can still get this disease. But overall numbers have dropped. And in the UK, we typically see something like 350 cases of bacterial meningitis per year. So that's basically one a day.

6:03Robin May:What's the distinction though, between that one a day and an outbreak?

6:09Kat Sharrocks:This is an interesting disease because it is transmitted particularly through kind of things like saliva between individuals. And so it's very important when we find even a single case of disease that we do what's called contact tracing. So for example, if there's a teenager who has been presented and diagnosed with bacterial meningitis, we will immediately start to look for, for example, members of their family, boyfriends, girlfriends, close friends with whom they may have had close contact in order to check for transmission and to treat those people. So even a single disease, we do follow up very closely.

6:40Kat Sharrocks:When we're talking about outbreaks, though, we're talking about multiple linked infections together. And so, for instance, if somebody's presented with a disease, sometimes their partner, the family members may get the same strain and that becomes an outbreak as it transmits and obviously our key role at the health security agency is to try and minimise the spread of that outbreak and treat the people affected as swiftly as possible.

7:02Robin May:Robin May at the UK HSA or UK Health Security Agency. We'll hear more from Robin a bit later on about how we respond in a public health capacity to cases of meningitis. But first the symptoms of bacterial meningitis usually appear quickly and they can mimic other common diseases like influenza. So what should we look out for and when might it be prudent to seek medical advice? I met Kat Sharrocks, who's a consultant in infectious diseases at Addenbrookes Hospital in Cambridge.

7:33Andrew Pollard:Usually what we're looking at is somebody who's got a fever, quite often got a headache, maybe have difficulty looking at the light, quite often has some neck stiffness. They might be a little bit confused. They might be a little bit sleepy as well. that's the general picture of somebody and that this has come on quite quickly it's not something that's been going on for days and days and days but it's quite often something that's happened in the last 24 hours.

7:59Robin May:Why is it then that people talk a lot about a rash with meningitis?

8:04Andrew Pollard:We can certainly see a rash with some sorts of meningitis but not having a rash doesn't mean that you don't have meningitis.

8:12Robin May:What's the cause of that though? Why would inflammation around your brain which is what's going on with meningitis be linked to a rash elsewhere on your body?

8:20Andrew Pollard:So that's what we can see with a systemic infection. Just because the infection's affecting one place, the meninges, those layers around the brain and the spinal cord, doesn't mean it's not affecting other places in the body. And particular bacteria and their toxins can cause problems with the clotting that we see in our bloodstream and that's what leads to that particular rash, that rash that doesn't go away when you put a glass on top of it. But that's not the only sort of rash that we can see. We can see lots of different rashes depending upon the bacteria that we see. So seeing that rash in and of itself by itself doesn't mean that you have meningitis, nor does not seeing it mean that you don't have meningitis.

9:00Robin May:Therefore, how do doctors like you get to the bottom of what is wrong with someone who's got that constellation of features?

9:07Andrew Pollard:So the first thing is that we've got to be aware of those constellation of features, as you say, and have a high suspicion for anybody who's presenting like this that they might have something as serious as meningitis. We'll examine them, so we'll look at their neck stiffness, we'll have a listen to their chest, but then we'll do some other more serious tests. We'll look at their blood markers, we'll see whether they have an infection by looking at their C-reactive protein perhaps, we'll look at their white blood cells to see if they've got raised white cells called neutrophils, which will be in keeping with having a bacterial infection.

9:38Andrew Pollard:We'll probably do some imaging of their head. First off would be a CT scan and that's really looking for other causes rather than meningitis that might cause a similar set of symptoms. And then we'll move towards doing a test called a lumbar puncture or a spinal tap, if you like the Americanisation of it, which is where we take a little sample of the fluid that surrounds the brain and the spinal cord and we look at that underneath the microscope. And we're looking again there for those white blood cells which shouldn't be there at all. We're looking to see whether they've crept into that space to try and fight an infection that shouldn't be there and then we'll test that fluid for other things.

10:17Andrew Pollard:We'll try and culture it to see if we can grow any bacteria in the laboratory and we'll look for other causes of the same constellation of symptoms, other causes of meningitis like looking for viruses as well as bacteria.

10:28Robin May:Why do they home into the meninges, those layers around the brain and spinal cord though in meningitis why do the bacteria make a beeline there do we know?

10:37Andrew Pollard:Different bacteria have different predilections for the places that they like to grow and the bacteria that go to the meninges have a predilection for those but there are also certain risk factors that you might have that make it more likely if you have one of these infections for them to go to the meninges. For example if your immune system doesn't work particularly well you may have a particular immune problem it may be that you are very young or that you're very very old where your immune system doesn't quite work as well as other people's. It might be that you have something like diabetes which can put you at a risk of having certain sort of infections or it may be that you have a little bit of a weaker immune system because of chronic use of alcohol for example.

11:17Robin May:If you pick it up, God forbid, and you discover there is all the evidence there is a bacterial infection there, what do you do?

11:25Andrew Pollard:So for most people even before we've got the evidence that this is definitely a bacterial meningitis, we will have started treatment. So we're aware that GPs, when they see this constellation of symptoms, even in their practices, they have antibiotics at hand that are able to treat meningitis and they'll give an intramuscular injection of antibiotics before sending the patient on their way to the hospital. Immediately in the hospital, for people where we suspect they have meningitis, we will start antibiotics at that point and we start a very broad spectrum antibiotic that's very good at getting into the central nervous system and we also usually start something called dexamethasone at the same time which is a steroid which might seem a little counterintuitive when you're trying to fight infection but that helps with inflammation that can cause longer term problems in bacterial meningitis.

12:16Robin May:And what tends to happen? How quickly do you know this person's going to turn the corner and how quickly before that person's better?

12:25Andrew Pollard:usually sort of say 24 to 48 hours of the appropriate antibiotics and we see some improvement if we're not seeing improvement at that point we tend to be very cautiously going back to the drawing board and ensuring that we have all the right sort of samples the antibiotics are getting to the right place and that we haven't missed anything because these infections although as we've said they target the meninges they can cause problems elsewhere and what about when it doesn't

12:53Robin May:go the right way. Does some cases actually end up with a bad outcome?

12:58Andrew Pollard:So not catching this early can end up with people unfortunately becoming very unwell and unfortunately despite having appropriate antibiotics they cannot make it and I've seen a couple of cases where people have come through the doors in an accident, an emergency and unfortunately passed away within sort of long minutes to short hours of having been there. For people where we've managed to get them on appropriate treatment and it's been a sort of series of days but despite that they aren't improving. We do try to optimize our antibiotics that we're using and as I was saying we try to find other places that the infection might be affecting.

13:35Andrew Pollard:The longer term outcomes there can be neurological difficulties after having such a degree of inflammation as well. We here would use our rehab teams, our neurological rehab teams to try and improve the outcomes of any deficit that we've seen after anybody's had an infection.

13:52Robin May:Kat Sharrick's at Adam Rooks Hospital in Cambridge there.

13:56Kat Sharrocks:The Naked Scientist podcast is produced in association with Spitfire, cost-effective voice, internet and IP engineering services for UK businesses. Find out how Spitfire can empower your company at spitfire.co.uk.

14:14Andrew Pollard:Music in the programme is sponsored by Epidemic Sound, perfect music for audio and video productions.

14:20Robin May:This is the Naked Scientist podcast with me Chris Smith and this week we are examining bacterial meningitis to find out what it is and how we respond to outbreaks. Just now we were hearing how to recognise, diagnose and treat cases of bacterial meningitis but prevention is always better than cure and this is where vaccines come in. Although the meningococcus is the most common cause there are a number of different bacteria that can cause meningitis and susceptibility to them tends to vary with age. Thankfully we do have a spectrum of very good vaccines against many of them now although because some of them have been introduced only relatively recently not everyone has received all of them and this is one factor that might underlie why the outbreak occurred recently in Kent.

15:10Robin May:I asked Professor Sir Andrew Pollard who is director of the Oxford Vaccine group to give us a roundup of what's being used and how effective they all are.

15:18Kat Sharrocks:The first vaccine to be introduced was against Haemophilus influenzae type B, that's given to babies. The second was a vaccine against pneumococcus, which is most commonly associated with pneumonia, but it's also one of the leading causes of meningitis in children and adults here in the UK. and the third vaccine for bacterial meningitis is against meningococcus and we have unfortunately to come to make it more complicated we have five different types of meningococcus one of the vaccines covers four of them and that's given to teenagers and then lastly against the b strain of meningococcus and that's a vaccine given to babies do we know though why some of these infections

Read the full transcript

16:05Robin May:with some of these particular bacterial causes are more common in certain age groups?

16:12Kat Sharrocks:The predominance of disease tends to be in early childhood. Most cases happen in those individuals who don't have any immunity in the first couple of years of life. And vaccines overcome that by helping the immune system recognise these bacteria, more like older are children and adults who are much more immune against these germs. And so if you vaccinate children, they're already prepared before the bacteria get into their nose and throat at the onset of this disease.

16:43Robin May:And what's actually in the vaccines, in this class of vaccine, what's in it that provokes the immune system and confers protection?

16:51Kat Sharrocks:They're a combination of the sugars that sit on the surface of the bacteria, combined onto a bit of protein, which is just helping the immune system recognise the sugars to make a strong immune response.

17:05Robin May:And how long is the protection that's conferred going to last for? So a person who gets vaccinated, say it's a young child having their MenB vaccine, how long are they going to be protected for, do we think?

17:16Kat Sharrocks:We have really good data showing that the protection is excellent for the first two years. And that's important because that's where almost all of the cases happen in early childhood. is in the first couple of years. For the vaccines given to teenagers, like the one that covers the other malingococcal types, ACW and Y, we have good evidence that that is protecting those teenagers through late teens into early adult life, which again is where the biggest risk is for them at universities and during their early 20s.

17:50Robin May:But in the recent outbreak in Kent, which was dominated by individuals of that particular age range, it was MenB back again, not those other strains. Is that because the immunity they had had, if they had the vaccine, the MenB vaccine as a baby, has worn off by then?

18:10Kat Sharrocks:Well, we only introduced the MenB vaccine back in 2015. So actually those affected are too old, even though they're still only teenagers and young adults, they're too old to have actually ever received the MenB vaccine. What we don't know at the moment is whether if you're vaccinated as an infant, it would still protect you one or two decades later. There's very limited evidence for ongoing protection after that length of time. And so there is a question about if we wanted to protect against MenB in teenagers and young adults, which clearly would be a great thing to do, and whether additional doses would be needed at that age.

18:50Robin May:one thing that many people were quite surprised by when there was coverage of the recent large outbreak in kent is how many individuals can carry these bacteria in their noses and throats and not get ill do the vaccines stop that carriage or do they just prevent you if you do end up carrying the bacterium not becoming really ill well this is the fascinating thing about these

19:18Kat Sharrocks:different bacteria we've just been discussing, that their actual normal state is living with us completely harmlessly and transmitting from one person to another. And one of the problems for the bacteria, in fact, one of the problems for us, is that the most efficient transmitters tend to also have features which make them more likely to get into our bloodstream. And that's only in a relatively small proportion of the population who are susceptible to getting that more severe disease. But it is an unfortunate side effect of the desire of these species to be able to just transmit between people.

19:54Kat Sharrocks:And in fact, with meningococcus, most of the carriage that happens in completely healthy people is in late teens and early adulthood. But that sort of pool of people carrying is what then spreads the bacteria in the rest of the population and explains why we get disease in other age groups who are not really the carriers.

20:14Robin May:Do these vaccines need periodic update or are the bacteria relatively stable? What they look like is the same today as it was a decade ago.

20:21Kat Sharrocks:Well, I think it's worth saying that the MenB vaccines that we have at the moment do work against these strains which cause the outbreak in Kent. So and although the bacteria can change over time, we're fortunate at the moment that this particular strain is covered by the vaccine. But one of the problems with MenB strains, because they do continue to vary over time, that you can have strains emerge where we don't think the vaccines would protect. so we do need to continue monitoring and and if over time a new strain emerged that wasn't covered by the two available men b vaccines then some serious thought would have to be given to updating the vaccines now to try to cover that newly emerged strain sir andrew pollard from the oxford vaccine

21:09Robin May:group as we heard earlier thanks to vaccination cases of bacterium meningitis have fallen markedly in countries like the UK in recent years. Nevertheless, sometimes there are still outbreaks and public health bodies like the UKHSA need to be ready to respond and they don't wait for evidence that the disease is spreading. With serious high-impact conditions like this one, a single case triggers a significant response. Robin May again.

21:36Kat Sharrocks:If you're a clinician with a patient with suspected meningitis, please don't wait for it to be confirmed. Get in touch with us. Health protection teams will reach out and assist with all the contact tracing. We'll contact family, friends, school, if it's relevant, people like that, and can start to coordinate. And importantly, the other thing that will happen in the background then is we'll be able to check whether that strain, once we have sequence information, is related to other strains. So we can look very closely at whether this may be connected to other cases elsewhere in the country, for example.

22:05Kat Sharrocks:And that can be important because as we've learned from the recent Kent outbreak, people often move quite widely within the UK. And so you can have apparently unrelated cases of disease that are actually connected by a single contact. And so understanding the most we can about the movements of the patient and the type of strain they have is really critical.

22:23Robin May:And when you get that genetic information, does that also not just reveal what bugs are related to what, so who may have given it to whom, but does it tell us anything about virulence, why this particular strain may or may not be nasty? does it tell us anything about whether it can slip through the net vaccine-wise or drug treatment-wise for antibiotics?

22:44Kat Sharrocks:Having that DNA information, that genome information is incredibly important. The first thing we can learn very, very swiftly actually without anywhere near full DNA information is the type of strain that's involved. So for example, is this a strain that we've seen circulating very commonly? Is it a rare strain? Is it something we haven't seen before? So we learn that quite fast. A more detailed genome sequence will start to tell us things about the bacteria itself. One of the things that we can make quite an accurate guess about when the sequence comes in is how effective current licensed vaccines might be against it.

23:17Kat Sharrocks:So we know, for example, what the vaccines that are used recognise, what the so-called epitape is they recognise, and we can look at that in the sequence strain and work out whether that epitape is the same and therefore whether it's likely to be covered well by the vaccine. really important to say that that's not 100 so we still need to then do the kind of laboratory experiments to work that out afterwards but you can make a kind of informed guess and then the third part i think is we can learn quite a lot about the possible virulence of this so there are factors so called virulence factors in bacteria that regulate things like how easy they are to transmit how well they might invade the human body whether they're going to be susceptible or not to antibiotics all of those things again we can kind of derive from the genome quite early on and get a good sense of how dangerous this strain may be, albeit again caveated by the fact that all these things need then verifying in real life.

24:06Kat Sharrocks:But having that ability to predict once you've got a sequence is really, really important.

24:10Robin May:And what is your strategy at that point? When you detect some cases, you discover that some may be linked. How do you then intervene at the level of whole communities to try to put a ring around this and stop it going farther afield?

24:23Kat Sharrocks:Yeah, sort of three parts to that, I think. And as we've seen in the recent Kent outbreak, all those three things happening at once. And the first and most critical thing is to treat people who may have been exposed to the bacteria and may be susceptible. So they will typically get a course of antibiotics. And you saw in the Kent outbreak that we treated literally thousands of people with antibiotics very swiftly for that reason. And that is designed to get rid of the bacteria that may have already transmitted to them and is growing without causing infection yet. So what we're trying to do essentially is to remove any risk to those individuals of the bacteria growing and causing meningitis in them.

24:56Kat Sharrocks:Secondly, in some cases, and you saw that in Kent, it makes sense also to do a so-called ring vaccination. So what we did in Kent is we offered a vaccine that we think is effective against this strain to those students too. That vaccine, importantly, does not eliminate the bacteria. So you can still carry the bacteria as a person who's vaccinated, but it will prevent you getting severe disease. So that's a good measure of protecting the individual, but it's not a good measure in preventing outbreak spread because you can still pass that bacteria on. So in the third part, as with all outbreaks, is then a very close monitoring of individuals.

25:29Kat Sharrocks:So knowing where they're travelling to, where they've been in contact with, and very, very accurate surveillance. And so all the time we are asking hospitals and healthcare staff to report back on possible cases and to check that genome information. And that is heightened, obviously, when we know there is a particularly worrisome strain available.

25:48Robin May:And just to finish, in the aftermath now, Now, what have we learned from what happened in Kent? Because it was an extraordinarily big outbreak. Why did it happen, do we think? And what's the prospect of this happening again?

26:00Kat Sharrocks:This is a very unusual outbreak. We typically see, as I said earlier, about one case a day. We had 22 cases in a few days. So it was a big outbreak, fast spreading, largely linked to people who attended a particular nightclub, students who attended a nightclub. So there are some things about the strain, if you look at the genome that are kind of potentially interesting, it's a little bit different to strains we've seen circulating. So there may be changes in the bacteria that's made it better able to spread. It'll be some time before we know that. We happen to do experiments at the minute, for example, to ask about things like persistence and transmission rate.

26:34So there

26:34Kat Sharrocks:might be something in the bacteria. There may also be something about the particular circumstances. So we know, for example, in Africa, where there's quite a lot of meningitis and the so-called meningitis belt. There is strong transmission during very dry weather and so one of the things we're looking at is whether there might be some sort of atmospheric conditions that might have contributed to this and then the third part is really this sort of social behaviour of things and one question is whether people's natural immunity to this strain may have dropped slightly either over time or because of Covid or because of something different about this strain and we have studies underway at the minute to look at natural immunity in the population and try and understand how much of that was a factor.

27:14Kat Sharrocks:Probably the answer will be some combination of all of these, but it's going to be some time, unfortunately, before we have a clear answer, I think.

27:21Robin May:Robin May, Chief Scientific Officer at the UK Health Security Agency, reassuring that they're on the case. That's it for this episode. We will have the latest science news stories from the week ready for you, though, on Friday, including why salmon might be getting hooked on cocaine in some of our waterways. That puts a whole new spin on the term fishing line, doesn't it and we'll also have our usual updates on linkedin instagram and x and if you'd like to support what we do then do please head over to nakedscientist.com forward slash donate your contributions help to keep up our running costs and your support as ever is hugely appreciated i'm chris smith thank you for listening and until next time goodbye

28:40Robin May:Thank you. friends. Happy hour done differently. Visit benihana.com. That's benihana.com.

From the publisher
Today, we put meningitis under the microscope. Robin May at the UK Health Security Agency explains this group of conditions and how his team might respond to an incident; Kat Sharrocks at Addenbrooke's Hospital details a range of symptoms associated with meningitis; and the Oxford Vaccine Group's Andrew Pollard on the protection that inoculation offers... Like this podcast? Please help us by supporting the Naked Scientists

More from The Naked Scientists Podcast

All 127 episodes
Meningitis under the microscopeThe Naked Scientists Podcast · 28 min
Listen in VO